What is Pulmonx Corp (LUNG) stock price today?

Pulmonx Corp (LUNG) currently trades at $1.28 per share. The stock has a market capitalization of $54.06M and a P/E ratio of —x.

Is LUNG stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Pulmonx Corp has a Smart Value Score of 37/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Pulmonx Corp's revenue and earnings?

Pulmonx Corp has trailing twelve-month (TTM) revenue of $90.50M with profit margins of -59.70%. Earnings per share (EPS) is $-1.34.

Is LUNG stock overvalued or undervalued?

Based on our DCF model, Pulmonx Corp's intrinsic value is $9.19, representing a margin of safety of 84.22%. The stock currently trades at a P/E of —x.

LUNG

Pulmonx Corp

NASDAQ: LUNG · HEALTHCARE · MEDICAL DEVICES

$1.28

+6.67% today

Updated 2026-04-30

Market cap

$54.06M

P/E ratio

—

P/S ratio

0.60x

EPS (TTM)

$-1.34

Dividend yield

—

52W range

$1 – $5

Volume

0.6M

Market cap

$54.06M

P/E ratio

—

P/S ratio

0.60x

EPS (TTM)

$-1.34

Dividend yield

—

52W range

$1 – $5

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

4.7

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$5.17

+303.91%

12-Month target

—

Intrinsic (DCF)

$9.19

Margin of safety

+84.22%

0 Strong Buy4 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 84.22% below intrinsic value

Risks

- Thin margins at -59.70%

- Negative free cash flow $-7.10M

- Revenue declining -4.90% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$53.66M	$68.67M	$83.79M	$90.50M	$90.50M
Net income	$-58.92M	$-60.84M	$-56.39M	$-54.00M	$-13.65M
EPS	—	—	—	—	$-1.34
Free cash flow	$-46.45M	$-38.42M	$-32.98M	$-32.90M	$-7.10M
Profit margin	-109.80%	-88.60%	-67.30%	-59.67%	-59.70%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LUNG	$54.06M	37	4.7	2.0	6.7	5.0	+84.22%	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Pulmonx Corp trades at $1.28. Our Smart Value Score of 37/100 indicates the stock is weak. TTM revenue stands at $90.50M. with profit margins at -59.70%. Our DCF model estimates intrinsic value at $9.19.

Frequently asked questions

What is Pulmonx Corp's stock price?

Pulmonx Corp (LUNG) trades at $1.28.

Is Pulmonx Corp overvalued?

Smart Value Score 37/100 (Grade D, Sell). DCF value $9.19.

What is the price target of Pulmonx Corp (LUNG)?

The analyst target price is $5.17, representing +303.9% upside from the current price of $1.28.

What is the intrinsic value of Pulmonx Corp (LUNG)?

Based on our DCF model, intrinsic value is $9.19, a +84.2% margin of safety versus $1.28.

What is Pulmonx Corp's revenue?

TTM revenue is $90.50M.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio0.60x

ROE-77.20%

Beta0.19

50D MA$1.46

200D MA$1.80

Shares out0.04B

Float0.04B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

LUNG vs LLY →LUNG vs JNJ →LUNG vs ABBV →Stock screener →